← Back to patent-cliff list
Vepugratinib
Tier C — Watch / tradeVepugratinib
Eli Lilly and Company
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FGFR3
Indications (approved)：Urothelial carcinoma, Bladder cancer, Metastatic cancer, Urinary tract neoplasm, Solid tumour, 输尿管肿瘤
Regional status
US
Phase III
2025-12-12
EU
Phase III
2025-12-12
China
Phase III
2025-12-12
Japan
Phase III
2025-12-12
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Vepugratinib?
Approved indications include: Urothelial carcinoma, Bladder cancer, Metastatic cancer, Urinary tract neoplasm, Solid tumour, 输尿管肿瘤.
When does the Vepugratinib patent expire?
No public expiry year is available for Vepugratinib yet; this page updates once verified.
How do I get a quote for Vepugratinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29